<code id='FDE385E851'></code><style id='FDE385E851'></style>
    • <acronym id='FDE385E851'></acronym>
      <center id='FDE385E851'><center id='FDE385E851'><tfoot id='FDE385E851'></tfoot></center><abbr id='FDE385E851'><dir id='FDE385E851'><tfoot id='FDE385E851'></tfoot><noframes id='FDE385E851'>

    • <optgroup id='FDE385E851'><strike id='FDE385E851'><sup id='FDE385E851'></sup></strike><code id='FDE385E851'></code></optgroup>
        1. <b id='FDE385E851'><label id='FDE385E851'><select id='FDE385E851'><dt id='FDE385E851'><span id='FDE385E851'></span></dt></select></label></b><u id='FDE385E851'></u>
          <i id='FDE385E851'><strike id='FDE385E851'><tt id='FDE385E851'><pre id='FDE385E851'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:29573
          Doctor sitting at a crowded desk. -- first opinion coverage from STAT
          Adobe

          SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.

          Making money outside of patient care — or “revenue diversification,” if you prefer industry jargon — has always made appearances on hospital slides at the annual investor conference in San Francisco. This year, though, hospital executives are projecting a sense of urgency around growing profit in other areas to make up for losing money on their bread and butter: taking care of patients in hospitals.

          advertisement

          “It used to be nice to have, but now it’s a must-have, especially for not-for-profit health systems,” Niyum Gandhi, the chief financial officer of Boston’s Mass General Brigham said in an interview with STAT after his presentation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          Sarepta Duchenne therapy fails to meet primary endpoint in trial
          Sarepta Duchenne therapy fails to meet primary endpoint in trial

          RubyWallauforSTATSareptaTherapeuticssaidMondayafternoonthatitsgenetherapyforDuchennemusculardystroph

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Key Senate panel to consider PBM, drug pricing reform package

          Sens.RonWydenandMikeCrapointroducedamentalhealth,PBMreformandsubstanceusepolicypackage.DrewAngerer/G